Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FEED
FEED logo

FEED Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.726
Open
0.726
VWAP
0.68
Vol
498.34K
Mkt Cap
4.42M
Low
0.630
Amount
336.84K
EV/EBITDA(TTM)
--
Total Shares
6.09M
EV
2.94M
EV/OCF(TTM)
--
P/S(TTM)
0.44
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
Show More

Events Timeline

(ET)
2026-05-18
17:20:00
ENvue Medical Files to Sell 6M Shares of Common Stock
select
2026-05-12 (ET)
2026-05-12
09:20:00
ENvue Medical Renews Three-Year Contract with Nonprofit Health System
select
2026-05-08 (ET)
2026-05-08
09:20:00
ENvue Medical Granted Patent for Novel Drug Delivery System
select
2026-05-07 (ET)
2026-05-07
10:00:00
ENvue Medical Renews Three-Year Purchasing Agreement with Major Non-Profit Health System
select
2026-04-20 (ET)
2026-04-20
08:40:00
ENvue Medical Launches Navigation Platform at Virginia Hospital
select
2026-04-16 (ET)
2026-04-16
09:30:00
ENvue Medical Issues Shareholder Letter, Outlook for 2026
select
2026-02-24 (ET)
2026-02-24
08:40:00
ENvue Medical Receives Patent Approval for Feeding Tube
select
2026-01-28 (ET)
2026-01-28
09:10:00
ENvue Medical Signs Distribution Agreement with U-Deliver
select
2026-01-21 (ET)
2026-01-21
08:40:00
ENvue Medical Appoints Marc Waldman as Vice President, Commercial
select

News

NASDAQ.COM
3.5
06-09NASDAQ.COM
ENvue Medical Launches AI Training Platform Ask Oscar for Feeding Tube Placement
  • AI Training Platform Launch: ENvue Medical has introduced Ask Oscar, an AI-powered training platform integrated into its patent-pending robotic feeding tube solution, ENvue Drive, aimed at enhancing medical efficiency through automated feeding tube placement workflows.
  • Market Opportunity Expansion: Ask Oscar is expected to be commercially available in the coming months and will be offered across ENvue's growing customer base, creating a scalable recurring revenue opportunity that enhances the company's competitive position in the market.
  • Training Efficiency Improvement: The platform will enable nurses, dietitians, and other clinicians to train on their own schedules, thereby accelerating the implementation of the ENvue Navigation Platform and addressing training bottlenecks that hinder the scaling of medical technology.
  • Real-Time Feedback Mechanism: Ask Oscar provides an interactive training environment that allows clinicians to practice and improve feeding tube placement skills through real-time guidance and objective performance feedback, significantly enhancing the accuracy and efficiency of clinical operations.
NASDAQ.COM
4.5
06-09NASDAQ.COM
Biotech Stocks Show Significant Pre-Market Activity
  • Market Opportunities: Biotech companies are experiencing significant pre-market activity on Tuesday, driven by plans for market launches, acquisitions, financing deals, and AI training program launches, indicating potential investment opportunities.
  • Notable Gains: Regentis Biomaterials Ltd. (RGNT) saw its stock price surge by 124% to $2.91, reflecting strong market confidence in its future growth and likely attracting more investor interest.
  • Significant Losses: Park Ha Biological Technology Co., Ltd. (BYAH) experienced a 39% decline in its stock price to $1.61, indicating market concerns about its business outlook, which may lead investors to reassess their investment strategies.
  • Increased Volatility: The price volatility among biotech stocks is heightened, particularly in the context of acquisitions and financing deals, prompting investors to closely monitor market dynamics to seize potential investment opportunities and risks.
Newsfilter
7.5
06-05Newsfilter
ENvue Medical Expands Navigation Platform to Burn ICU in Major Health Network
  • Technology Expansion: ENvue Medical announced the expansion of its Navigation Platform into the burn intensive care unit of a major U.S. academic health network, marking the second deployment within the same system and enhancing access to technology for complex patient populations.
  • Clinical Trust: CEO Doron Besser stated that the health network's decision reflects the clinical versatility of the ENvue platform and the institutional trust earned, as clinical teams have successfully integrated the platform into their workflows, building confidence in its performance.
  • Growing Market Demand: ENvue's VP Marc Waldman noted an increasing demand from health systems looking to modernize feeding tube placement, with the expansion into the burn center showcasing the broad clinical applicability of the ENvue platform and indicating future growth potential in similar institutions.
  • Technological Advantage: The ENvue Navigation Platform is a minimally invasive electromagnetic navigation system that is FDA 510(k) cleared, enabling real-time visualization of feeding tube movement, supporting clinical decision-making, and enhancing patient safety and care quality.
Newsfilter
7.5
04-20Newsfilter
ENvue Medical Platform Adopted by New Hospital
  • Hospital Adoption: A 255-bed nonprofit medical center in Virginia has begun using the ENvue™ Navigation Platform, marking ENvue's 40th U.S. hospital customer and further expanding its influence across regional health systems.
  • Nursing Model Transition: The hospital is performing feeding tube placements through a nursing-led bedside model, reducing reliance on interventional radiology, thereby enhancing efficiency and aligning with the growing trend of patient-centered care in the healthcare industry.
  • Real-Time Visualization Benefits: The ENvue™ Navigation Platform provides real-time bedside visualization, assisting clinical teams in making informed decisions during feeding tube placements, addressing hospitals' needs for greater consistency and visibility in procedures, and promoting standardized practices.
  • Growing Market Demand: ENvue Medical's VP Marc Waldman noted an increasing demand for technologies that can be implemented across care teams, indicating a rising market focus on non-invasive solutions, which suggests significant potential for future commercial expansion.
Benzinga
9.5
01-29Benzinga
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
  • Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
  • Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
  • Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
  • Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
stocktwits
7.5
01-28stocktwits
ENvue Partners with U-Deliver for Nationwide Syringe Distribution
  • Stock Surge: ENvue Medical, Inc. (FEED) shares soared 138% on Wednesday following the announcement of a distribution agreement with U-Deliver, indicating strong market enthusiasm for its new product line.
  • Product Launch: The recently launched ENFit syringe line is designed to meet clinical needs for both feeding and medication delivery without requiring a prescription, enhancing its competitive edge in the market.
  • Distribution Channel Expansion: The new agreement will leverage U-Deliver's digital and wholesale channels to broaden access to the ENFit syringes, which is expected to significantly increase market penetration.
  • Market Sentiment Shift: On Stocktwits, retail sentiment around FEED shifted from 'bearish' to 'extremely bullish', with message volume rising from 'low' to 'extremely high', reflecting investor optimism about the company's future prospects.

Valuation Metrics

The current forward P/E ratio for ENvue Medical Inc (FEED.O) is 0.00, compared to its 5-year average forward P/E of -0.00. For a more detailed relative valuation and DCF analysis to assess ENvue Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.00
Current PE
0.00
Overvalued PE
-0.00
Undervalued PE
-0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.88
Current PS
0.00
Overvalued PS
1.04
Undervalued PS
0.72

Financials

AI Analysis
Annual
Quarterly

Whales Holding FEED

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is ENvue Medical Inc (FEED) stock price today?

The current price of FEED is 0.6715 USD — it has decreased -7.57

What is ENvue Medical Inc (FEED)'s business?

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

What is the price predicton of FEED Stock?

Wall Street analysts forecast FEED stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ENvue Medical Inc (FEED)'s revenue for the last quarter?

ENvue Medical Inc revenue for the last quarter amounts to 653.00K USD, decreased -36.29

What is ENvue Medical Inc (FEED)'s earnings per share (EPS) for the last quarter?

ENvue Medical Inc. EPS for the last quarter amounts to -6.88 USD, decreased -76.99

How many employees does ENvue Medical Inc (FEED). have?

ENvue Medical Inc (FEED) has 12 emplpoyees as of June 21 2026.

What is ENvue Medical Inc (FEED) market cap?

Today FEED has the market capitalization of 4.42M USD.